CD274 and Ewing sarcoma: For instance, immune checkpoint inhibitors aim to restore immune recognition of tumor cells by targeting pathways such as PD-1/PD-L1 and CTLA-4, with combination strategies being investigated to enhance their efficacy given the relatively low mutational burden of Ewing sarcoma and lack of PD-L1 expression in EwS tumors [4].